GlassScriptPhysician profile
Stephanie Johnston
NPI 1407229628
$24,795.41
in general payments reported to CMS, 2019-2025
59 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,166 · 2022: $12K · 2023: $6,281 · 2024: $2,294 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,301 · Food and Beverage: $4,054 · Education: $995 · Travel and Lodging: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,301.00 |
| Food and Beverage | $4,053.67 |
| Education | $994.54 |
| Travel and Lodging | $709.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $8,532.01 | 2022-2025 | |
| Lilly USA, LLC | $2,781.82 | 2021-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $1,910.47 | 2021-2023 | Imbruvica, Epkinly |
| Seagen INC. | $1,576.01 | 2021-2024 | Tukysa |
| Pfizer INC. | $781.94 | 2021-2025 | |
| Incyte Corporation | $781.29 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Scientific Affairs, LLC | $780.00 | 2022 | |
| Celgene Corporation | $504.10 | 2021-2025 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $446.03 | 2021-2025 | Erleada |
| Astrazeneca Pharmaceuticals LP | $416.12 | 2022-2025 | Imfinzi, Lynparza |
| Aveo Pharmaceuticals, INC. | $398.93 | 2021-2025 | Fotivda |
| Genzyme Corporation | $391.61 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $379.37 | 2021-2025 | Opdivo |
| Astellas Pharma US INC | $312.84 | 2021-2024 | Padcev |
| Abbvie INC. | $281.52 | 2021-2025 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.